Ophiomics is committed to innovation, conducting and participating in research projects aiming at developing better diagnostic services, better able to serve the patient and the medical community. This research is conducted at Ophiomics and in collaboration with clinical and academic centres. Our primary areas of research are Clinical Bioinformatics, Biomarkers, Decision Algorithms in Medicine and Clinical Genomics.

The rapid development of DNA sequencing technologies and widespread adoption by clinical genetics laboratories results in massive amounts of data for which robust and informative bioinformatics analysis are required for clinical use. Ophiomics’s R&D activity is focused on models of data analyses, visualisation and clinical interpretation. We are particularly interested in decision support systems in the clinical laboratory context, specifically on making explicit decision trees, automating decisions, using machine learning to support decision systems, human-machine interface and data integration.  An outcome of our R&D work in this domain is the development of a clinical genomics and genetics software. We are interested in collaborations with academic groups that have interesting solutions and that could be translated for clinical use.

The other area of Ophiomics’ R&D focus is the identification of biomarkers that, associated to clinical variables, can support the development of better decision algorithms, that enable safer and better decision making by the clinical. Our primary area of research is Oncology, specifically the stratification of patients for specific treatments and/or personalised monitoring schemes. Our preferred model of work is collaborating with clinical teams with know how on a specific disease/clinical context and access to sample/patients, to which we bring our technical and commercial development know how and experience. Our most advanced and flagship program is HepatoPredict.

Our third area of work in Clinical Genomics, where we focus on the technical development and optimisation of Liquid Biopsies. This non-invasive alternative/complement to tradicional tissue biopsies raises multiple laboratory and bioinformatics challenges that interdigitate with the two previous previous areas of research. This topic is exclusively developed internally, and focused on developing the Precision Oncology Portfolio of the Germano de Sousa Group.